Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05030974
Other study ID # NL78963.042.21
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 21, 2021
Est. completion date March 12, 2022

Study information

Verified date March 2022
Source University Medical Center Groningen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rationale: The humoral and cellular immune response after two mRNA vaccinations is severely attenuated in kidney transplant patients compared to controls, especially when their immunosuppressive regimen contains mycophenolate mofetil (MMF) / mycophenolic acid (MPA). A repeated dose strategy is therefore required to improve the efficacy of vaccination. Objective: To investigate the immunogenicity of third or fourth dose SARS-CoV-2 vaccination strategies in kidney transplant patients. Study design: Prospective, multicentre, open-label randomized clinical trial Study population: Patients with a functioning kidney transplant who did not seroconvert after two or three doses of a mRNA vaccine (either mRNA-1273 (Moderna) or BNT162b2 (Pfizer) or any combination of both) Procedures: Based on their immunosuppressive treatment, patients can participate in one of the following strata: - stratum A: patients receiving triple immunosuppressive therapy, consisting of a calcineurin inhibitor, MMF/MPA, and steroids In stratum A, patients will be randomized to one of two equally sized groups. Patients will receive a third or fourth vaccination of the mRNA-1273 vaccine (100 μg, i.m), with either continuation of MMF/MPA (A1) or discontinuation of MMF/MPA during one week before and one week after the third or fourth dose, respectively (A2). - stratum B: patients receiving any combination of immunosuppressive drugs. In stratum B, patients will be randomized to one of three equally sized groups. Patients will receive another dose (100 μg, i.m) of the mRNA-1273 vaccine (B1), or two single doses of mRNA-1273 into the left and the right upper arm (2 x 100 μg, i.m; B2), or the Ad26.COV2.S vaccine (Janssen, 5x1010 viral particles, i.m; B3). Main study parameters/endpoints: The primary endpoint is the proportion of patients with an anti-S1 antibody concentration higher than 10 BAU/mL established at 28 days after the third or fourth vaccine administration. Within each stratum different vaccination strategies will be compared. Secondary endpoints include: - concentration of anti-S1 antibodies in serum at 28 days after the 3rd or 4th vaccine administration - concentration of virus-neutralizing antibodies in serum - SARS-CoV-2 specific T cell responses - safety in terms of incidence of acute rejection and solicited local and systemic adverse events (AEs) after vaccination. - antibody (IgG and IgA) responses in nasal mucosal fluid


Description:

2. OBJECTIVES Primary objective: To assess the immunogenicity (expressed as percentage of responders) of various COVID-19 third or fourth vaccination strategies in kidney transplant patients that failed to mount a sufficient antibody response after two or three primary doses of a mRNA vaccine (either mRNA-1273 (Moderna) or BNT162b2 (Pfizer) or any combination of both). Secondary Objectives: - To measure the concentration of SARS-CoV-2 spike S1-specific IgG antibodies in serum at 28 days after the 3rd or 4th vaccine administration - To measure the presence and titer of neutralizing anti-SARS-CoV-2 antibodies after third or fourth vaccination - To evaluate SARS-CoV-2 specific T cell responses - To measure anti-S1 antibody (IgG and IgA) responses and neutralizing capacity of these antibodies in nasal mucosal fluid - To evaluate vaccine safety in terms of incidence of solicited local and systemic adverse events (AEs) graded according to severity. Exploratory Objectives: - To assess the association between baseline clinical and immunological parameters and the immune response to third or fourth vaccinations - To correlate RNA-seq data at one week after vaccination to the subsequent antibody and T cell response 3. STUDY DESIGN This is a prospective, multicentre, open-label, randomized study to evaluate the immunogenicity and safety of various third or fourth vaccination strategies in kidney transplant patients without a sufficient antibody response after two or three primary doses of a mRNA vaccine (either mRNA-1273 (Moderna) or BNT162b2 (Pfizer) or any combination of both). The four participating study sites are: Amsterdam UMC, ErasmusMC, Radboudumc and UMCG. Based on their immunosuppressive treatment, patients will participate in one of the following strata: - stratum A: patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, - stratum B: patients treated with any combination of immunosuppressive drugs. In stratum A, patients will be randomized to one of two third or fourth vaccination strategies: - A1: one extra dose of mRNA-1273 (100 μg, i.m) - A2: one extra dose of mRNA-1273 (100 μg, i.m), with temporary discontinuation of MMF/MPA during one week before and one week after the 3rd dose In stratum B, patients will be randomized to one of three third vaccination strategies: - B1: 3rd dose of mRNA-1273 (100 μg, i.m) - B2: 3rd dose of mRNA-1273 (100 μg, i.m) in both upper arms - B3: Ad26.COV2.S vaccine (Janssen, 5x1010 viral particles i.m.) To assess the immune response after vaccination, blood samples will be collected at baseline (i.e. prior to third dose administration) and at 28 days after the third or fourth dose administration. A complete blood count, kidney function, and liver enzymes will be determined at the same time points. In a subset of patients we will collect a blood sample at 1 week after the third vaccin administration for specific immunological assays. For safety reasons, a blood sample will be collected in stratum A at one and two weeks after discontinuing MMF/MPA. The maximum volume of blood collected for this study is 66 mL per timepoint, and no more than 200 mL for the one year study period, which is well within the safe limits of blood collection for clinical studies. Nasal mucosal lining fluid (MLF) will be collected for assessment of secreted mucosal antibodies at the same time points used to collect blood. MLF will be collected by use of soft synthetic absorptive matrix (SAM) strips, which are gently inserted into one nostril of the participant and placed along the surface of the inferior turbinate. The index finger is then lightly pressed against the side of the nostril to keep the SAM strip in place and to allow MLF absorption for 60 seconds, after which the SAM strip is placed back in the protective plastic tube. The procedure may tickle slightly but is completely painless. To evaluate vaccination related AEs, patients will be asked to collect solicited local and systemic AEs for 7 days after each vaccination using a questionnaire, as vaccination related AEs are mainly expected in the first week after vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 336
Est. completion date March 12, 2022
Est. primary completion date March 12, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age 18 years or older 2. Received 2 doses of mRNA-1273 (stratum B) according to the recommended vaccination schedule, with the last administration within the last nine months. For stratum A, also patients who received 2 doses of BNT162b2 and/or a third dose with a mRNA vaccine (mRNA-1273 or BNT162b2) within the last three months are eligible. 3. At least 6 months after kidney transplantation 4. Negative seroresponse 14 to 56 days after vaccination, measured by a validated anti-spike IgG assay of which the definition is dependent on the assay that is used. 5. Eligible for COVID-19 vaccination as described by the instructions of the manufacturers of the vaccine (Moderna and Janssen) 6. Capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed informed consent form has been obtained) 7. Willing to adhere to the protocol and be available during the study period Additional inclusion criteria to be eligible for stratum A: 8. Maintenance immunosuppressive therapy consisting of a calcineurin inhibitor (tacrolimus or cyclosporine), MMF/MPA, and prednisone 9. In case of tacrolimus treatment: last tacrolimus pre-dose level while on current dosage above 4 µg/l 10. In case of cyclosporine treatment: last cyclosporine pre-dose level while on current dosage above 75 µg/l 11. Prednisone dose at least 5 mg/day 12. First or second transplantation 13. Calculated level of panel reactive antibodies prior to last transplantation below 85% 14. No signs of acute rejection during the preceding year Exclusion Criteria: 1. Multi-organ transplant recipient 2. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s). 3. Previous or active COVID-19 disease 4. Active malignancy, except non-melanoma skin cancer 5. Inherited immune deficiency 6. Infection with Human Immunodeficiency Virus (HIV) 7. Administration of T cell, B cell, or plasma cell depleting antibodies during the last 6 months 8. Any vaccination within a week before enrolment 9. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. Additional exclusion criteria for stratum B: 10. History of recurrent venous thrombosis or venous thrombosis <2 years before baseline 11. Immune-mediated diseases associated with thrombocytopenia such as ITP and aHUS

Study Design


Intervention

Biological:
mRNA-1273
SARS-CoV-2 vaccination
Ad26.COV2.S vaccine
SARS-CoV-2 vaccination

Locations

Country Name City State
Netherlands Amsterdam UMC Amsterdam Noord-Holland
Netherlands University Medical Center Groningen Groningen
Netherlands Radboud umc Nijmegen Gelderland
Netherlands Erasmus mc Rotterdam Zuid-Holland

Sponsors (5)

Lead Sponsor Collaborator
University Medical Center Groningen Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Erasmus Medical Center, Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Relation between age and immune response The association between age and development of an antibody and/or T cell response after third or fourth vaccine administration 28 days after vaccination
Other Relationship between time after transplant and immune response The association between time after transplantation and development of an antibody and/or T cell response after third or fourth vaccine administration 28 days after vaccination
Other Relationship between immunosuppressive medication and immune response The association between baseline immunosuppressive medication and development of an antibody and/or T cell response after third or fourth vaccine administration 28 days after vaccination
Other Relationship between lymphocytes and immune response The association between baseline lymphocytes and development of an antibody and/or T cell response after third or fourth vaccine administration 28 days after vaccination
Other Relationship between eGFR and immune response The association between baseline eGFR and development of an antibody and/or T cell response after third or fourth vaccine administration 28 days after vaccination
Other SARS-CoV-2 reactive CD4+ and CD8+ cells Flow cytometry of PBMC for measuring SARS-CoV-2 reactive CD4+ and CD8+ cells after third or fourth vaccine administration 28 days after vaccination
Other Early gene expression for SARS-CoV-2 immune response RNA-seq analysis to detect early gene expression that are associated with the development of an antibody and/or T cell response after third or fourth vaccine administration 28 days after vaccination
Other Incidence of COVID-19 breakthrough infection Measured by questionnaires and SARS-CoV-2 nucleocapsid specific antibodies 28 days after vaccination
Primary Positive SARS-CoV-2 seroresponse The percentage of subjects with a serum anti-S1 IgG concentration =10 BAU/mL after the third or fourth vaccine administration 28 days after third vaccination
Secondary SARS-CoV-2 antibody concentration SARS-CoV-2 anti-S1 IgG concentration in serum after third or fourth vaccine administration 28 days after vaccination
Secondary Virus-neutralizing capacity of SARS-CoV-2 antibodies The titer of neutralizing anti-SARS-CoV-2 antibodies after third or fourth vaccine administration 28 days after vaccination
Secondary Mucosal SARS-CoV-2 antibodies Concentrations of SARS-CoV-2 specific antibodies (IgG and IgA) in nasal fluid after third or fourth vaccine administration 28 days after vaccination
Secondary SARS-CoV-2 specific T cell response Interferon-gamma concentration in whole blood after ex vivo stimulation with SARS-CoV-2 specific peptides
Ex vivo production of T cell related cytokines by peripheral blood mononuclear cells (PBMC) in ELISpot assays after third vaccine administration
28 days after vaccination
Secondary Solicited local and systemic adverse events Percentage of participants reporting local reactions (pain at the injection site, redness and swelling) and systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, new of worsened muscle pain, and new or worsened joint pain) after third or fourth vaccine administration within 7 days after vaccination
Secondary Serious adverse events Percentage of participants with serious adverse events after third or fourth vaccine administration within 28 days after vaccination
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3